Skip to content

Lisa M. Burke

4 papers in the library · 1,133 citations · publishing 2019-2026

Papers

Sort Most recent Most cited

Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland.

The International Journal of Neuropsychopharmacology June 2, 2026 John R. Kelly, Christopher Sheridan, Patricia Iusan et al.

Classical serotonergic psychedelics, such as psilocybin, show emerging evidence of therapeutic potential across a range of mental health disorders, including depression, anxiety, and substance use disorders, with indications of transdiagnostic efficacy. While early-phase studies yielded encouraging results, recent larger-scale phase 3 trials, such as those evaluating psilocybin for...

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.

The New England journal of medicine November 3, 2022 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. 1,095 citations

Psilocybin is being studied for use in treatment-resistant depression. In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support. The primary end point was the change from baseline to week 3 in the...

Psychedelic science in post-COVID-19 psychiatry

Irish Journal of Psychological Medicine August 19, 2020 John R. Kelly, Matthew Crockett, Laith Alexander et al. 16 citations

The medium- to long-term consequences of COVID-19 are not yet known, though an increase in mental health problems are predicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19. Preliminary evidence from the rapidly progressing field of psychedelic science shows that psilocybin therapy offers a promising...

The psychedelic renaissance: the next trip for psychiatry?

Irish Journal of Psychological Medicine September 23, 2019 John R. Kelly, Annie Baker, Mona Babiker et al. 22 citations

The psychedelic research renaissance is gaining traction. Preliminary clinical studies of the hallucinogenic fungi, psilocybin, with psychological support, have indicated improvements in mood, anxiety and quality of life. A seminal, open-label study demonstrated marked reductions in depression symptoms in participants with treatment-resistant depression (TRD). The associated neurobiological...